Table 2.
Characteristics of patients with SARS-CoV-2 (Omicron variant) infection according to vaccine status: management and outcomes during hospital stay
| Vaccinated (N = 746) | Unvaccinated (N = 469) | p | |
|---|---|---|---|
| Requirement for oxygen, n (%) | 385 (51.6) | 304 (64.8) | <0.001 |
| Maximal oxygen flow (L/min) | 4.0 [2.0-10.0] | 7.0 [3.0-15.0] | <0.001 |
| Duration of oxygen therapy (d) | 5.0 [2.0-10.0] | 7.0 [4.0-11.8] | <0.001 |
| High-flow oxygen, n (%) | 32 (4.4) (n = 729) | 56 (12.0) (n = 468) | <0.001 |
| Steroid therapy | |||
| Prescribed n (%) | 297 (40.0) (n = 743) | 275 (58.8) (n = 468) | <0.001 |
| Median Dose (IQR) | 7.5 [6.0–11.1] (n = 290) | 8.0 [6.0–12.0] (n = 273) | 0.009 |
| Duration (d) | 5.0 [3.0-10.0] (n = 286) | 8.0 [4.0-10.0] (n = 272) | <0.001 |
| Tocilizumab, n (%) | 20 (2.7) (n = 745) | 29 (6.2) | 0.004 |
| Monoclonal Ab, n (%)a | 30 (4.0) (n = 745) | 19 (4.1) (n = 467) | 1.000 |
| Antiviral use, n (%)b | 27 (5.2) (n = 516) | 25 (7.0) (n = 355) | 0.336 |
| ICU admission, n (%) | 60 (8.0) | 72 (15.4) | <0.001 |
| ICU duration (d) | 7.0 [3.0-15.0] | 9.0 [5.0-15.0] | 0.095 |
| Invasive mechanical ventilation, n (%) | 17 (2.3) (n = 740) | 22 (4.7) (n = 464) | 0.030 |
| Invasive mechanical ventilation duration (d) | 5.0 [2.5-12.5] | 8.0 [7.0-20.0] | 0.037 |
| Death at day 28, n (%) | 71 (9.5) | 62 (13.2) | 0.044 |
| Death at day 28 and/or ICU admission, n (%) | 113 (15.2) | 116 (24.7) | <0.001 |
| Length of stay (d) | 7.0 [3.0-14.0] (n = 571) | 8.0 [4.0-13.0] (n = 377) | 0.472 |
Quantitative variables are presented as median (first quartile to third quartile). When data were missing, the number of patients out of whom the percentage was calculated is mentioned alongside the percentage. Ab, antibody; ICU, intensive care unit; IQR, interquartile range.
Among the 30 vaccinated patients who received monoclonal antibodies, 55.6% and 44.4% received tixagevimab/cilgavimab and sotrovimab, respectively. Among the 19 unvaccinated patients, 85.7% and 14.3% received tixagevimab/cilgavimab and sotrovimab, respectively.
Among the 27 vaccinated patients who received antiviral, 78.6% received remdesivir and 21.4% favipiravir. Among the 25 unvaccinated patients who received an antiviral, 57.7% received remdesivir and 42.3% received favipiravir.